← Leaderboards
Anuradha Roy
University Of Kansas Lawrence
$3,203,725
Attributed
$6,690,554
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,690,554 · 4
By mechanism
R01$5,730,640 · 3
P20$959,914 · 1
Top collaborators
- Frank Schoenen7 shared
- Nancy A Muma5 shared
- Michal Zolkiewski4 shared
- Andrew K Godwin3 shared
Most similar at University Of Kansas Lawrence
Same institution · by research overlap
- William D. Picking$9,452,694
- Roberto N De Guzman$7,172,876
- Mark Steven Cohen$1,514,123
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseCellsScreeningSmall MoleculeHigh Throughput ScreeningPublic HealthBiologyResponseProteinsIn VitroCytotoxicityEvaluationInhibitor/AntagonistBindingKansasLibrariesAreaMicrobialBiologicalCommunicable DiseasesBiochemicalAssay DevelopmentFunding OpportunitiesSmall Molecule Inhibitor
Grant awards (17)
Infectious Disease Assay Development Core$207,508
P20 · FY2025 · GM · contact PI
Infectious Disease Assay Development Core$204,623
P20 · FY2024 · GM · contact PI
Infectious Disease Assay Development Core$181,287
P20 · FY2023 · GM · contact PI
Discovery of Hsp100-selective inhibitors for targeting multiple microbial pathogens$328,714
R01 · FY2022 · AI
Infectious Disease Assay Development Core$183,163
P20 · FY2022 · GM · contact PI
Discovery of Hsp100-selective inhibitors for targeting multiple microbial pathogens$479,141
R01 · FY2021 · AI
Infectious Disease Assay Development Core$183,333
P20 · FY2021 · GM · contact PI
Discovery of Hsp100-selective inhibitors for targeting multiple microbial pathogens$589,070
R01 · FY2020 · AI
Targeting Kinesin Family Member 15 for the Treatment of Cancer$553,464
R01 · FY2019 · CA
Discovery of Hsp100-selective inhibitors for targeting multiple microbial pathogens$514,035
R01 · FY2019 · AI
Targeting Kinesin Family Member 15 for the Treatment of Cancer$623,043
R01 · FY2018 · CA
HTS to identify small molecules to disrupt abnormal huntingtin interactions in HD$497,360
R01 · FY2018 · NS
HTS to identify small molecules to disrupt abnormal huntingtin interactions in HD$11,499
R01 · FY2018 · NS
Targeting Kinesin Family Member 15 for the Treatment of Cancer$641,589
R01 · FY2017 · CA
HTS to identify small molecules to disrupt abnormal huntingtin interactions in HD$474,579
R01 · FY2017 · NS
HTS to identify small molecules to disrupt abnormal huntingtin interactions in HD$512,946
R01 · FY2016 · NS
HTS to identify small molecules to disrupt abnormal huntingtin interactions in HD$505,200
R01 · FY2015 · NS